What is the current Alnylam Pharmaceuticals Inc (ALNY) share price?

Alnylam Pharmaceuticals Inc last traded at $293.17 with a market capitalisation of about $39.1B.

What is the analyst price target for ALNY?

The mean analyst price target for Alnylam Pharmaceuticals Inc is $436.32, roughly 48.8% above the latest price. The current consensus rating is “Buy”.

Is ALNY expensive on a P/E basis?

Alnylam Pharmaceuticals Inc currently trades on a price-to-earnings ratio of 184.8, with a price-to-book of 35.5.

Where can I see Alnylam Pharmaceuticals Inc's full financial metrics?

Luminoso tracks ALNY's valuation, profitability, efficiency, leverage and earnings-quality metrics alongside analyst data — updated daily. Create a free account to explore the full breakdown.

Alnylam Pharmaceuticals Inc (ALNY) Stock Forecast

US · Healthcare

Current price

$293.17

Market cap

$39.14B

Mean price target

$436.32

Implied upside

48.8%

Key takeaways

Analysts rate Alnylam Pharmaceuticals Inc a “Buy”, with a mean price target of $436.32 — about 48.8% upside from the current $293.17, based on 25 analysts.
ALNY is trading near its 52-week low, at 9% of the $273.11–$495.55 band.
On valuation, ALNY trades at a premium P/E of 184.8 and an EV/EBITDA of 124.1.
Profitability looks respectable: return on equity is 19.2%, with a free-cash-flow margin of 4.2%.
Its balance sheet looks solid, with a current ratio of 3.13. Net debt/EBITDA stands at -1.4x.

Analyst consensus

Consensus rating	Buy
Number of analysts	25
Mean target	$436.32
High target	$550.00
Low target	$310.00
Rating split (SB / B / H / S / SS)	6 / 14 / 8 / 0 / 0

Price & trading

Current price	$293.17
Previous close	$294.06
52-week high	$495.55
52-week low	$273.11
50-day average	$298.39
Beta	0.27

Valuation

P/E ratio	184.78
P/B ratio	35.54
EV / EBITDA	124.08
Dividend yield	0.0%
Revenue per share	$8.75
Book value per share	$8.06

Profitability

Return on equity (ROE)	19.2%
Return on assets (ROA)	4.0%
Return on invested capital (ROIC)	42.4%
Free-cash-flow margin	4.2%
FCF yield	0.1%

Financial health

Current ratio	3.13
Quick ratio	3.06
Debt / equity	3.77
Net debt / EBITDA	-1.44
Interest coverage	4.20
Altman Z-score	4.97

See the full ALNY breakdown on Luminoso

Valuation, profitability, efficiency, leverage & earnings-quality metrics — updated daily.

Start free — 2 months on us

Frequently asked questions

What is the current Alnylam Pharmaceuticals Inc (ALNY) share price?: Alnylam Pharmaceuticals Inc last traded at $293.17 with a market capitalisation of about $39.1B.
What is the analyst price target for ALNY?: The mean analyst price target for Alnylam Pharmaceuticals Inc is $436.32, roughly 48.8% above the latest price. The current consensus rating is “Buy”.
Is ALNY expensive on a P/E basis?: Alnylam Pharmaceuticals Inc currently trades on a price-to-earnings ratio of 184.8, with a price-to-book of 35.5.
Where can I see Alnylam Pharmaceuticals Inc's full financial metrics?: Luminoso tracks ALNY's valuation, profitability, efficiency, leverage and earnings-quality metrics alongside analyst data — updated daily. Create a free account to explore the full breakdown.

More stocks

Browse all companies covered by Luminoso →

Last updated 25 Jun 2026.

Data is provided for informational purposes only and is not investment advice. Figures are cached and refreshed daily; they may differ from real-time quotes.